MDS Nordion launches Theryttrex in E.U

Canadian radioisotope supplier MDS Nordion of Kanata, ON, introduced Theryttrex, the company's radiopharmaceutical-grade yttrium-90 (Y-90) product, at the German Congress of Nuclear Medicine in Rostock, Germany.

Theryttrex is used as a precursor to radiolabeled Zevalin (marketed and distributed in Europe by Schering AG of Berlin), the first radioimmunotherapeutic product approved in the E.U. for the treatment of non-Hodgkin's lymphoma, according to the firm.

By staff writers
April 22, 2004

Related Reading

MDS Nordion offers new radioisotopes, March 2, 2004

MDS revamps for Q4, October 29, 2003

MDS records Q3 uptick in Life Sciences group, September 4, 2003

MDS Nordion inks licensing deal, August 12, 2003

MDS Nordion brings new cyclotron online, June 17, 2003

Copyright © 2004

Page 1 of 436
Next Page